Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients
Abstract Objectives This study was conducted to investigate the clinical significance of Slit2 and Robo1 expression in prognosis of patients with brain gliomas. Methods Human brain tissue samples were collected from normal glial tissues (control), low- and high-grade glioma tissues. Slit2 and Robo1...
Gespeichert in:
| Veröffentlicht in: | Surgical oncology 2016-12, Vol.25 (4), p.405-410 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 410 |
|---|---|
| container_issue | 4 |
| container_start_page | 405 |
| container_title | Surgical oncology |
| container_volume | 25 |
| creator | Liu, Liqiang Li, Wenhua Geng, Shaomei Fang, Yanwei Sun, Zhimin Hu, Hongchao Liang, Zhaohui Yan, Zhongjie |
| description | Abstract Objectives This study was conducted to investigate the clinical significance of Slit2 and Robo1 expression in prognosis of patients with brain gliomas. Methods Human brain tissue samples were collected from normal glial tissues (control), low- and high-grade glioma tissues. Slit2 and Robo1 expression levels in cells were assessed by an immunohistochemistry (IHC), and population of the Slit2- and Robo1-presenting patients was examined. The Slit2 and Robo1 mRNA expression levels in three types of the brain cells was determined by RT-PCR. Results Slit2+ cell counts were decreased with increased Robo1+ cells in the low-grade and high-grade glioma tissues as compared to the control. The percentage of cells expressing Slit2 decreased from the control to the high-grade glioma and the percentage of cells expressing Robo1 in low- and high-grade gliomas was increased as compared to the control (P |
| doi_str_mv | 10.1016/j.suronc.2016.09.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846024484</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960740416301141</els_id><sourcerecordid>1846024484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-22741aff2ff8a0725d9ef3007591c178bf3d43c7bff19163d0782d694ce2e44c3</originalsourceid><addsrcrecordid>eNqFkUuLFDEQgBtR3HH1H4gEvHjptvKYTvdFkGV9wILg6sFTSKcrQ2Z7kjHVLe6_N-2sCnvxkpDkq0e-qqrnHBoOvH29b2jJKbpGlFMDfQMgH1Qb3um-llLAw2oDfQu1VqDOqidEewBoteCPqzOhe95yLTfVt-spzILZOLLPaUic4c9jRqKQIrPEhpAONt9gJuZTLje0vsUdO-a0i4kCsRDZkG1Zd9MKs6OdA8aZnlaPvJ0In93t59XXd5dfLj7UV5_ef7x4e1U7pbZzLYRW3HovvO8saLEde_QSQG977rjuBi9HJZ0evOelaTmC7sTY9sqhQKWcPK9enfKWlr4vSLM5BHI4TTZiWsjwTrUglOpUQV_eQ_dpybF0t1JayVaCLJQ6US4noozeHHMoFm4NB7OqN3tzUm9W9QZ6A7_DXtwlX4YDjn-D_rguwJsTgMXGj4DZkCumHI4ho5vNmML_KtxP4KYQg7PTDd4i_fuLIWHAXK_jX6dfrAHnistfNTCrGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1847436303</pqid></control><display><type>article</type><title>Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Liu, Liqiang ; Li, Wenhua ; Geng, Shaomei ; Fang, Yanwei ; Sun, Zhimin ; Hu, Hongchao ; Liang, Zhaohui ; Yan, Zhongjie</creator><creatorcontrib>Liu, Liqiang ; Li, Wenhua ; Geng, Shaomei ; Fang, Yanwei ; Sun, Zhimin ; Hu, Hongchao ; Liang, Zhaohui ; Yan, Zhongjie</creatorcontrib><description>Abstract Objectives This study was conducted to investigate the clinical significance of Slit2 and Robo1 expression in prognosis of patients with brain gliomas. Methods Human brain tissue samples were collected from normal glial tissues (control), low- and high-grade glioma tissues. Slit2 and Robo1 expression levels in cells were assessed by an immunohistochemistry (IHC), and population of the Slit2- and Robo1-presenting patients was examined. The Slit2 and Robo1 mRNA expression levels in three types of the brain cells was determined by RT-PCR. Results Slit2+ cell counts were decreased with increased Robo1+ cells in the low-grade and high-grade glioma tissues as compared to the control. The percentage of cells expressing Slit2 decreased from the control to the high-grade glioma and the percentage of cells expressing Robo1 in low- and high-grade gliomas was increased as compared to the control (P < 0.01). The decrease in the Slit2 mRNA expression was associated with the increase in the Robo1 mRNA expression in the low- and high-grade gliomas (P < 0.01 or 0.05). Survival time for patients with Slit2- /Robo1+ gliomas was shorter than patients with Slit2+ /Robo1+ gliomas in the investigated cohorts (P < 0.01). Conclusion Slit2 and Robo1 expression levels serve as a biomarker with utility in grading gliomas as well as predicting patient survival. The change in Slit2 expression is more reliable and effective than Robo1 expression in predicting a poor prognosis of brain glioma patients.</description><identifier>ISSN: 0960-7404</identifier><identifier>EISSN: 1879-3320</identifier><identifier>DOI: 10.1016/j.suronc.2016.09.003</identifier><identifier>PMID: 27916173</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Aged ; Alcohol ; Biomarkers, Tumor - metabolism ; Brain cancer ; Brain gliomas ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain research ; Case-Control Studies ; Cell division ; Female ; Follow-Up Studies ; Glioma - metabolism ; Glioma - pathology ; Hematology, Oncology and Palliative Medicine ; Hospitals ; Humans ; Immunoenzyme Techniques ; Intercellular Signaling Peptides and Proteins - metabolism ; Male ; Medical prognosis ; Middle Aged ; Neoplasm Grading ; Nerve Tissue Proteins - metabolism ; Patients ; Prognosis ; Proteins ; Receptors, Immunologic - metabolism ; Robo1 ; Roundabout Proteins ; Slit2 ; Surgery ; Survival proportion and prognosis of gliomas ; Survival Rate ; Traumatic brain injury ; Tumors</subject><ispartof>Surgical oncology, 2016-12, Vol.25 (4), p.405-410</ispartof><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-22741aff2ff8a0725d9ef3007591c178bf3d43c7bff19163d0782d694ce2e44c3</citedby><cites>FETCH-LOGICAL-c445t-22741aff2ff8a0725d9ef3007591c178bf3d43c7bff19163d0782d694ce2e44c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.suronc.2016.09.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27916173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Liqiang</creatorcontrib><creatorcontrib>Li, Wenhua</creatorcontrib><creatorcontrib>Geng, Shaomei</creatorcontrib><creatorcontrib>Fang, Yanwei</creatorcontrib><creatorcontrib>Sun, Zhimin</creatorcontrib><creatorcontrib>Hu, Hongchao</creatorcontrib><creatorcontrib>Liang, Zhaohui</creatorcontrib><creatorcontrib>Yan, Zhongjie</creatorcontrib><title>Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients</title><title>Surgical oncology</title><addtitle>Surg Oncol</addtitle><description>Abstract Objectives This study was conducted to investigate the clinical significance of Slit2 and Robo1 expression in prognosis of patients with brain gliomas. Methods Human brain tissue samples were collected from normal glial tissues (control), low- and high-grade glioma tissues. Slit2 and Robo1 expression levels in cells were assessed by an immunohistochemistry (IHC), and population of the Slit2- and Robo1-presenting patients was examined. The Slit2 and Robo1 mRNA expression levels in three types of the brain cells was determined by RT-PCR. Results Slit2+ cell counts were decreased with increased Robo1+ cells in the low-grade and high-grade glioma tissues as compared to the control. The percentage of cells expressing Slit2 decreased from the control to the high-grade glioma and the percentage of cells expressing Robo1 in low- and high-grade gliomas was increased as compared to the control (P < 0.01). The decrease in the Slit2 mRNA expression was associated with the increase in the Robo1 mRNA expression in the low- and high-grade gliomas (P < 0.01 or 0.05). Survival time for patients with Slit2- /Robo1+ gliomas was shorter than patients with Slit2+ /Robo1+ gliomas in the investigated cohorts (P < 0.01). Conclusion Slit2 and Robo1 expression levels serve as a biomarker with utility in grading gliomas as well as predicting patient survival. The change in Slit2 expression is more reliable and effective than Robo1 expression in predicting a poor prognosis of brain glioma patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Alcohol</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Brain cancer</subject><subject>Brain gliomas</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain research</subject><subject>Case-Control Studies</subject><subject>Cell division</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glioma - metabolism</subject><subject>Glioma - pathology</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Intercellular Signaling Peptides and Proteins - metabolism</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Receptors, Immunologic - metabolism</subject><subject>Robo1</subject><subject>Roundabout Proteins</subject><subject>Slit2</subject><subject>Surgery</subject><subject>Survival proportion and prognosis of gliomas</subject><subject>Survival Rate</subject><subject>Traumatic brain injury</subject><subject>Tumors</subject><issn>0960-7404</issn><issn>1879-3320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUuLFDEQgBtR3HH1H4gEvHjptvKYTvdFkGV9wILg6sFTSKcrQ2Z7kjHVLe6_N-2sCnvxkpDkq0e-qqrnHBoOvH29b2jJKbpGlFMDfQMgH1Qb3um-llLAw2oDfQu1VqDOqidEewBoteCPqzOhe95yLTfVt-spzILZOLLPaUic4c9jRqKQIrPEhpAONt9gJuZTLje0vsUdO-a0i4kCsRDZkG1Zd9MKs6OdA8aZnlaPvJ0In93t59XXd5dfLj7UV5_ef7x4e1U7pbZzLYRW3HovvO8saLEde_QSQG977rjuBi9HJZ0evOelaTmC7sTY9sqhQKWcPK9enfKWlr4vSLM5BHI4TTZiWsjwTrUglOpUQV_eQ_dpybF0t1JayVaCLJQ6US4noozeHHMoFm4NB7OqN3tzUm9W9QZ6A7_DXtwlX4YDjn-D_rguwJsTgMXGj4DZkCumHI4ho5vNmML_KtxP4KYQg7PTDd4i_fuLIWHAXK_jX6dfrAHnistfNTCrGA</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Liu, Liqiang</creator><creator>Li, Wenhua</creator><creator>Geng, Shaomei</creator><creator>Fang, Yanwei</creator><creator>Sun, Zhimin</creator><creator>Hu, Hongchao</creator><creator>Liang, Zhaohui</creator><creator>Yan, Zhongjie</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients</title><author>Liu, Liqiang ; Li, Wenhua ; Geng, Shaomei ; Fang, Yanwei ; Sun, Zhimin ; Hu, Hongchao ; Liang, Zhaohui ; Yan, Zhongjie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-22741aff2ff8a0725d9ef3007591c178bf3d43c7bff19163d0782d694ce2e44c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alcohol</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Brain cancer</topic><topic>Brain gliomas</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain research</topic><topic>Case-Control Studies</topic><topic>Cell division</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glioma - metabolism</topic><topic>Glioma - pathology</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Intercellular Signaling Peptides and Proteins - metabolism</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Receptors, Immunologic - metabolism</topic><topic>Robo1</topic><topic>Roundabout Proteins</topic><topic>Slit2</topic><topic>Surgery</topic><topic>Survival proportion and prognosis of gliomas</topic><topic>Survival Rate</topic><topic>Traumatic brain injury</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Liqiang</creatorcontrib><creatorcontrib>Li, Wenhua</creatorcontrib><creatorcontrib>Geng, Shaomei</creatorcontrib><creatorcontrib>Fang, Yanwei</creatorcontrib><creatorcontrib>Sun, Zhimin</creatorcontrib><creatorcontrib>Hu, Hongchao</creatorcontrib><creatorcontrib>Liang, Zhaohui</creatorcontrib><creatorcontrib>Yan, Zhongjie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Liqiang</au><au>Li, Wenhua</au><au>Geng, Shaomei</au><au>Fang, Yanwei</au><au>Sun, Zhimin</au><au>Hu, Hongchao</au><au>Liang, Zhaohui</au><au>Yan, Zhongjie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients</atitle><jtitle>Surgical oncology</jtitle><addtitle>Surg Oncol</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>25</volume><issue>4</issue><spage>405</spage><epage>410</epage><pages>405-410</pages><issn>0960-7404</issn><eissn>1879-3320</eissn><abstract>Abstract Objectives This study was conducted to investigate the clinical significance of Slit2 and Robo1 expression in prognosis of patients with brain gliomas. Methods Human brain tissue samples were collected from normal glial tissues (control), low- and high-grade glioma tissues. Slit2 and Robo1 expression levels in cells were assessed by an immunohistochemistry (IHC), and population of the Slit2- and Robo1-presenting patients was examined. The Slit2 and Robo1 mRNA expression levels in three types of the brain cells was determined by RT-PCR. Results Slit2+ cell counts were decreased with increased Robo1+ cells in the low-grade and high-grade glioma tissues as compared to the control. The percentage of cells expressing Slit2 decreased from the control to the high-grade glioma and the percentage of cells expressing Robo1 in low- and high-grade gliomas was increased as compared to the control (P < 0.01). The decrease in the Slit2 mRNA expression was associated with the increase in the Robo1 mRNA expression in the low- and high-grade gliomas (P < 0.01 or 0.05). Survival time for patients with Slit2- /Robo1+ gliomas was shorter than patients with Slit2+ /Robo1+ gliomas in the investigated cohorts (P < 0.01). Conclusion Slit2 and Robo1 expression levels serve as a biomarker with utility in grading gliomas as well as predicting patient survival. The change in Slit2 expression is more reliable and effective than Robo1 expression in predicting a poor prognosis of brain glioma patients.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27916173</pmid><doi>10.1016/j.suronc.2016.09.003</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-7404 |
| ispartof | Surgical oncology, 2016-12, Vol.25 (4), p.405-410 |
| issn | 0960-7404 1879-3320 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1846024484 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Alcohol Biomarkers, Tumor - metabolism Brain cancer Brain gliomas Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain research Case-Control Studies Cell division Female Follow-Up Studies Glioma - metabolism Glioma - pathology Hematology, Oncology and Palliative Medicine Hospitals Humans Immunoenzyme Techniques Intercellular Signaling Peptides and Proteins - metabolism Male Medical prognosis Middle Aged Neoplasm Grading Nerve Tissue Proteins - metabolism Patients Prognosis Proteins Receptors, Immunologic - metabolism Robo1 Roundabout Proteins Slit2 Surgery Survival proportion and prognosis of gliomas Survival Rate Traumatic brain injury Tumors |
| title | Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A27%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Slit2%20and%20Robo1%20expression%20as%20biomarkers%20for%20assessing%20prognosis%20in%20brain%20glioma%20patients&rft.jtitle=Surgical%20oncology&rft.au=Liu,%20Liqiang&rft.date=2016-12-01&rft.volume=25&rft.issue=4&rft.spage=405&rft.epage=410&rft.pages=405-410&rft.issn=0960-7404&rft.eissn=1879-3320&rft_id=info:doi/10.1016/j.suronc.2016.09.003&rft_dat=%3Cproquest_cross%3E1846024484%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1847436303&rft_id=info:pmid/27916173&rft_els_id=S0960740416301141&rfr_iscdi=true |